10家跨国头部药企公开2025年上半年财报,强生突破400亿美元大关

动脉网
Aug 06, 2025

截至2025年8月6日,10家跨国头部药企公布了上半年财报,其中强生以400亿美元的收入领跑,主要得益于其创新制药业务特别是肿瘤药物达雷妥尤单抗的强劲表现。罗氏紧随其后,实现收入373.62亿美元,制药业务增长显著,特别是乳腺癌和血液癌症药物贡献突出。默沙东收入为313.35亿美元,但其核心产品“K药”帕博利珠单抗的增速放缓,HPV疫苗销售额大幅下降。诺和诺德以18%的销售额增长位列增速首位,收入...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10